Companies › PeproMene Bio
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BAFFR-CAR T cells BAFFR-targeting CAR T cell therapy | TNFRSF13C | Phase 1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04690595 | BAFFR-CAR T cells | Phase 1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Oncology | Nov 2026 |
| NCT05370430 | BAFFR-CAR T cells | Phase 1 | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Oncology | Jul 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.